AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03120299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
Study NCT03120299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
Study NCT00005845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given PO
Study NCT00005845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00005845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00999141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FS VH S/D 4 s-apr
Description: FS VH S/D 4 s-apr will be applied (using spray device provided by Sponsor) to the subcutaneous plane (intraoperative, topical administration) in both the neck and the face area.
Study NCT02815137 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Digital Polymerase Chain Reaction
Description: Determination of mutation of XPO1 E571K by digital PCR in blod sample of patient with classical hodgkin lymphoma
Study NCT02929316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: IV infusion week 0, 2 and 6
Study NCT02427958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Description: Suspension for injection.
Study NCT00204516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA coding for melanoma associated antigens
Description: mRNA vaccine s.c. applied weekly
Study NCT00204516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Given s.c. as adjuvant drug one day after vaccine
Study NCT00711607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nomegestrol acetate and estradiol
Description: Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
Study NCT01323504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Patient are listen music during their local care
Study NCT01323504 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: no music
Description: There are no music during the local care
Study NCT01481519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone 0.1%/povidone-iodine 0.4%
Description: dexamethasone 0.1%/povidone-iodine 0.4%
Study NCT01481519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Tears
Description: artificial tears 1 drop, 4 times per day
Study NCT00143741 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin (Lipitor)
Description: 20mg every day, taken by mouth. Dose could be increased up to 60mg every day during the course of the trial if tests indicate this is needed.
Study NCT04152395 — intervention group
Intervention type: OTHER
Intervention: EVAR
Description: Patients undergoing EVAR
Study NCT01334762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole/IUI
Description: Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
Study NCT01334762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC/IUI
Description: Patients received 100 mg lCC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
Study NCT03847922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide + Oxygen Gas (Product)
Description: Self-administered 50% nitrous oxide / 50% oxygen mixture will be given to the intervention group, starting just before the beginning of the urethral bulking procedure.
Study NCT03847922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine gel 2%
Description: 6mL of 2% lidocaine gel will be inserted and injected into the urethral canal approximately 10 minutes prior to the procedure for each participant regardless of group assignment.
Study NCT03847922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine gel 2%
Description: 6mL of 2% lidocaine gel will be inserted and injected into the urethral canal approximately 10 minutes prior to the procedure for each participant regardless of group assignment.
Study NCT03847922 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Room air
Description: Room air will be administered via the Pro-Nox machine to participants in the control group, starting just before the beginning of the urethral bulking procedure.
Study NCT03723915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03723915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wild-type Reovirus
Description: Given pelareorep IV
Study NCT04677933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: OLP-1002
Description: 10 patients will receive 5 µg OLP-1002 twice-weekly (BIW) OLP-1002
Study NCT04677933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: OLP-1002
Description: 10 patients will receive 10 µg OLP-1002 BIW OLP-1002
Study NCT04677933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: Placebo
Description: 10 patients will receive Placebo BIW
Study NCT01246050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HF training
Description: These are CBOC Providers who received HF Training as the active intervention. HF training includes didactic lectures, case discussions and interactive symposia, course materials including teaching material, textbooks, copies of HF clinical guidelines and patient education material for distribution, participation in HF Clinics and Inpatient Heart Failure Rounds. Providers were given access to clinical pharmacist services Including medication and disease teaching, adjustment and uptitration. There was quarterly analysis of patient compliance including individualized confidential, non-punitive feedback to providers from a set of prespecified core HF performance measures.
Study NCT01246050 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No HF training
Description: These are control providers drawn from the same CBOCs who have not received HF training, access to clinical pharmacist medication titration services or performance feedback
Study NCT05742659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A mobile-based interactive simulation scheme (MISS)
Description: A mobile-based interactive simulation scheme (MISS) was proposed and developed to investigate its effects on facilitating hands-on learning of NG insertion in undergraduate medical students.
Study NCT04113928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli & mustard seed soup
Description: 200ml acute feed
Study NCT04113928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli & mustard seed soup
Description: 200ml acute feed
Study NCT04113928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli soup
Description: 200ml acute feed
Study NCT04113928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli soup
Description: 200ml acute feed
Study NCT00941109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Cohort 1: 30 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
Study NCT00941109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Cohort 2: 60 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
Study NCT00941109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Cohort 3: 120 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
Study NCT00941109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Cohort 4: 240 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
Study NCT03168490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten Friendly bread
Description: parallel study
Study NCT03168490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gluten Friendly bread
Description: parallel study
Study NCT01262924 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine
Description: Intramuscular, single dose
Study NCT01262924 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' reduced-antigen-content acellular pertussis vaccine
Description: Intramuscular, single dose
Study NCT01262924 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tedivax-Adult™/ Td-Rix™
Description: Intramuscular, single dose or 2 doses (in the annex phase)
Study NCT03172364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micellar cleanser
Description: Participants will apply the micellar cleanser topically twice a day (morning and evening). Micellar cleanser will be applied on cotton pad and wiped over the entire face and closed eye to gently cleanse. No need to rub or rinse the micellar cleanser.
Study NCT03172364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micellar foaming cleanser
Description: Participants will use the micellar foaming cleanser topically twice a day (morning and evening). Micellar foaming cleanser will be massaged gently onto wet skin on the face using fingertips. After which participants will rinse thoroughly and pat the skin dry.
Study NCT02362347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: London Health Sciences Centre - Compression Vest
Description: London Health Sciences Centre - Compression Vest
Study NCT02362347 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: exercise
Study NCT02362347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise
Study NCT03023852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive JNJ-63623872 600 mg (2\*300 mg) oral tablets in Panel 1 and 2 under Fasted conditions.
Study NCT02791646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training Full
Description: Pain Coping Skills Training Full(PCST-Full) will consist of a 5-session intervention delivered to participants at the medical center by their therapist.
Study NCT02791646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Brief
Description: Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
Study NCT02954822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin→Evogliptin+Glimepiride→Glimepiride
Description: Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days. After the washout period for 10 days, Glimepiride 4mg will be administered for 2 days.~Glimepiride : Glimepiride 4mg QD~Evogliptin + Glimepiride : Evogliptin 5mg QD + Glimepiride 4mg QD
Study NCT02954822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride→Evogliptin→Evogliptin+Glimepiride
Description: After 2 days of administration of Glimepiride 4mg follows the 10-day washout period. Afterwards Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days.
Study NCT02155075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRA device imaging
Description: MIRA device imaging for adjunctive detection of breast cancer. Arm 1 administarte result
Study NCT02301039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02713854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial biopsy
Description: An endometrial biopsy taken 2-3 months prior to IVF cycle
Study NCT00798018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine
Description: lidocaine: 2%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
Study NCT00798018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Air injected into the cuff to seal the space between the trachea and the tube at minimal volume
Study NCT00798018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% tetracaine
Description: tetracaine: 1%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
Study NCT00798018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N.S
Description: 0.9% Normal saline injected into the cuff to seal the space between the trachea and the tube at minimal volume
Study NCT02779660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: RIPC will be induced by the application of 3 short episodes (5 minutes) of forearm ischemia by cuff sphygmomanometer inflation separated by 5 minutes of reperfusion.
Study NCT02779660 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham-intervention
Description: In the control group the cuff will be inflated for 3 times at 10 mm Hg for 5 minutes with 5-minute intervals
Study NCT04621838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned interventions.
Description: Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use, with Silicone Foam Dressing and Silicone Foam Lite Dressing.~The patients will be evaluated at each dressing change over a six-week period (per Product) or until the wound is healed to extent that the use of the Silicone Foam and Silicone Foam Lite dressing is no longer indicated from the time that the patient has been recruited.
Study NCT01054391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEC - Neurovascular Embolization Cover
Description: Implantation of NEC for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistuale arising from a parent vessel of 2.5 to 4.5mm
Study NCT03630913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tagged axillary metastatic node
Description: First, initially metastatic lymph node is tagged with a metal clip under sonography. Then, patients receive NAC before surgery.~Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC.~SLN isotope detection is performed with or without blue dye. All patients undergo the resection of the tagged axillary node, SLN biopsy and a complementary axillary lymphadenectomy.
Study NCT01153620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lavasept 0.04%
Description: Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Lavasept® 0.04% 50 ml 50ml or as much needed to completely saturate the compress.~Treatment Duration 60 minutes
Study NCT01153620 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's Solution
Description: Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Ringers' solution 50ml or as much needed to completely saturate the compress. Treatment Duration 60 minutes
Study NCT05248724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: periarticular infiltration (50ml) with Ropivacaine Hydrochloride 10 MG/ML (200 mg) + ketorolac tromethamine 30 mg/ml (30 mg) + adrenaline 1mg/ml (300 microgram) + morphine hydrochloride 10mg/ml (5 mg)
Description: Patients allocated to the intervention group received a periarticular infiltration with a solution containing 200 mg of ropivacaine hydrochloride ,150 mg if the patient weight was below 65kg, 5 mg of morphine hydrochloride , 30 mg of ketorolac tromethamine, 300 micrograms of adrenaline and saline 0.9% till reaching 50 ml of volume. Half of the solution was injected into the proximal hamstring stump. The surgical team closed the wounds and injected the other half of the intervention into the subcutaneous tissue in the distal wound and portals. There was not any medication introduced inside the articulation. Patients of the placebo group were treated in the same way, but the solution injected was 50 ml of saline 0.9%.
Study NCT05248724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 50 ml of 0.9 saline
Study NCT02669914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Study NCT00822224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEOPA
Description: inhalation of MEOPA during the painful care
Study NCT04201678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CLIA Group (conventional local anesthesia infiltration)
Description: The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the CLIA group, the needle (50 mm 22 Gauge) was directed towards the laminar periosteum at the pedicular projection point at the 10-15 ° angle with the sagittal plane. A mixture of 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be applied bilaterally.
Study NCT04201678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EPIAA Group (Extrapedicular infiltration anesthesia)
Description: The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~The anesthesia process of the CLIA + EPIA group also includes the third step called EPIA. For this stage, the anesthetic needle (50 mm 22 Gauge) is first drawn into the subcutaneous tissue, then through the lateral superior articular process to the lateral half of the pedicle and the upper border of the transverse process (5-10 degrees with sagittal plane and 5-10 with coronal plane), and after negative aspiration 3 mL 2% Lidocaine Hydrochloride and 7 mL 0.5% bupivacaine mixture will be applied bilaterally
Study NCT04201678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP Group (Erector Spina Block)
Description: The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the ESP group, a high-frequency-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally at the point of application. Once the erector spinae muscle and transverse process have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane was opened. Bilateral 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be administered.
Study NCT03023852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Participants will receive Oseltamivir 75 mg (1\*75 mg) oral capsule (reference) in Treatment D of Panel 2 and Oseltamivir 75 mg administered as JNJ-63623872/37.5 mg Oseltamivir oral FDC tablet concept formulation (test 3) in Treatment E of Panel 2.
Study NCT05866341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nitrate-rich lettuce juice
Description: Consumption of a daily dosage of 200 mg nitrate via the consumption of a 300mö of a nitrate-rich lettuce juice
Study NCT05866341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: nitrate-depleted lettuce juice
Description: Daily consumption of 300 ml of a nitrate-depleted lettuce juice
Study NCT00096109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT00096109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04300322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical pessary
Description: Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
Study NCT04300322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Progesterone
Description: Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
Study NCT00679549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Therapy
Description: CPAP therapy is provided as an inpatient.
Study NCT04652011 — intervention group
Intervention type: PROCEDURE
Intervention: Minimally Invasive Gynecologic Surgery
Description: Minimally Invasive Surgery for gynecologic disease (laparoscopy, robotic surgery, vaginal surgery)
Study NCT04652011 — intervention group
Intervention type: PROCEDURE
Intervention: osteopathic manipulative treatment
Description: Osteopathic manipulative treatment
Study NCT04652011 — intervention group
Intervention type: DRUG
Intervention: Pain killer
Description: Common pain killer (paracetamol, Ibuprofen, ketoprofen)
Study NCT01801462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based training